Donor-derived stem cell infusion for sustained pancytopenia after CD19 CAR-T therapy for relapsed patients post allogeneic stem cell transplantation.

Yingying Li Yixue Li Mingming Zhang Houli Zhao Miaoyong Zhu He Huang Yongxian Hu

Published in: European journal of haematology (2023)

Donor-derived CAR-T cell therapy is safe and effective in patients with relapsed/refractory ALL after allo-HSCT. Donor-derived PBSCs infusion could achieve hematopoietic recovery with controllable aGVHD in patients with persistent pancytopenia.

Keyphrases

stem cell transplantation
cell therapy
stem cells
high dose
acute lymphoblastic leukemia
acute myeloid leukemia
end stage renal disease
low dose
diffuse large b cell lymphoma
multiple myeloma
bone marrow
ejection fraction
chronic kidney disease
prognostic factors
mesenchymal stem cells
patient reported outcomes